Your browser doesn't support javascript.
loading
The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
Veenstra, Cynthia; Karlsson, Elin; Mirwani, Sanam Mirwani; Nordenskjöld, Bo; Fornander, Tommy; Pérez-Tenorio, Gizeh; Stål, Olle.
Afiliación
  • Veenstra C; Division of Clinical Sciences, Department of Clinical and Experimental Medicine and Department of Oncology, Faculty of Health Sciences, Linköping University, 581 85, Linköping, Sweden. cynthia.veenstra.liu@gmail.com.
  • Karlsson E; Division of Clinical Sciences, Department of Clinical and Experimental Medicine and Department of Oncology, Faculty of Health Sciences, Linköping University, 581 85, Linköping, Sweden.
  • Mirwani SM; Division of Clinical Sciences, Department of Clinical and Experimental Medicine and Department of Oncology, Faculty of Health Sciences, Linköping University, 581 85, Linköping, Sweden.
  • Nordenskjöld B; Division of Clinical Sciences, Department of Clinical and Experimental Medicine and Department of Oncology, Faculty of Health Sciences, Linköping University, 581 85, Linköping, Sweden.
  • Fornander T; Department of Oncology-Pathology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
  • Pérez-Tenorio G; Division of Clinical Sciences, Department of Clinical and Experimental Medicine and Department of Oncology, Faculty of Health Sciences, Linköping University, 581 85, Linköping, Sweden.
  • Stål O; Division of Clinical Sciences, Department of Clinical and Experimental Medicine and Department of Oncology, Faculty of Health Sciences, Linköping University, 581 85, Linköping, Sweden.
J Cancer Res Clin Oncol ; 145(7): 1845-1856, 2019 Jul.
Article en En | MEDLINE | ID: mdl-31025094
PURPOSE: The protein tyrosine phosphatase PTPN2 dephosphorylates several tyrosine kinases in cancer-related signalling pathways and is thought to be a tumour suppressor. As PTPN2 is not frequently studied in breast cancer, we aimed to explore the role of PTPN2 and the effects of its loss in breast cancer. METHODS: Protein expression and gene copy number of PTPN2 were analysed in a cohort of pre-menopausal breast cancer patients with immunohistochemistry and droplet digital PCR, respectively. PTPN2 was knocked down in three cell lines, representing different breast cancer subtypes, with siRNA transfection. Several proteins related to PTPN2 were analysed with Western blot. RESULTS: Low PTPN2 protein expression was found in 50.2% of the tumours (110/219), gene copy loss in 15.4% (33/214). Low protein expression was associated with a higher relapse rate in patients with Luminal A and HER2-positive tumours, but not triple-negative tumours. In vitro studies further suggested a subtype-specific role of PTPN2. Knockdown of PTPN2 had no effect on the triple-negative cell line, whilst knockdown in MCF7 inhibited phosphorylation of Met and promoted that of Akt. Knockdown in SKBR3 led to increased Met phosphorylation and decreased Erk phosphorylation as well as EGF-mediated STAT3 activation. CONCLUSION: We confirm previous studies showing that the PTPN2 protein is lost in half of the breast cancer cases and gene deletion occurs in 15-18% of the cases. Furthermore, the results suggest that the role of PTPN2 is subtype-related and should be further investigated to assess how this could affect breast cancer prognosis and treatment response.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteína Tirosina Fosfatasa no Receptora Tipo 2 Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: J Cancer Res Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteína Tirosina Fosfatasa no Receptora Tipo 2 Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: J Cancer Res Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Alemania